Host defense peptides as new weapons in cancer treatment
Host defense peptides as new weapons in cancer treatment
复制标题
DOI：
10.1007/s00018-005-4560-2
复制
发表时间：
2005-04-01
影响因子：
8
通讯作者：
Shai, Y
中科院分区：
文献类型：
--
作者：
Papo, N;Shai, Y
在过去的十年中，人们进行了大量研究以确定先天免疫宿主防御肽（也称为抗菌肽）在杀死原核和真核细胞中的作用。许多抗菌肽会破坏细胞膜，作为其杀伤机制的一部分。然而，目前尚不清楚是什么使癌细胞对其中一些肽更敏感，以及这些活性背后的分子机制是什么。提出了两种一般机制：（i）通过胶束化或孔形成破坏质膜，以及（ii）通过线粒体膜破坏诱导细胞凋亡。为了临床使用，这些肽需要将高特异性抗癌活性与血清稳定性结合起来。尽管到目前为止还非常有限，但新的研究为具有新作用模式和广谱抗癌活性的有前景的抗癌宿主防御肽铺平了道路
In the last decade intensive research has been conducted to determine the role of innate immunity host defense peptides (also termed antimicrobial peptides) in the killing of prokaryotic and eukaryotic cells. Many antimicrobial peptides damage the cellular membrane as part of their killing mechanism. However, it is not clear what makes cancer cells more susceptible to some of these peptides, and what the molecular mechanisms underlying these activities are. Two general mechanisms were suggested: (i) plasma membrane disruption via micellization or pore formation, and (ii) induction of apoptosis via mitochondrial membrane disruption. To be clinically used, these peptides need to combine high and specific anticancer activity with stability in serum. Although so far very limited, new studies have paved the way for promising anticancer host defense peptides with a new mode of action and with a broad spectrum of anticancer activity